



ASX & MEDIA RELEASE
29 JUNE, 2012

MARSHALL EDWARDS ANNOUNCES NAME CHANGE TO MEI PHARMA ("MEIP")

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL), has made the following announcement:

San Diego – 28 June, 2012 – Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it will change its name to MEI Pharma, Inc. and its common stock will begin trading under the new ticker symbol MEIP when the market opens on Monday, 2 July, 2012.

"Over the past two years we have successfully relocated our headquarters to the US, acquired a robust intellectual property portfolio, assembled world-class drug development expertise and advanced our two most promising oncology candidates into clinical trials," said Daniel P Gold PhD, President and Chief Executive Officer of Marshall Edwards. "Now, with our drug candidates poised for the next phase of clinical development and our company in a position for growth, it is time for a name that reflects our identity and more effectively conveys our purpose."

The company's common stock will be assigned a new CUSIP number of 55279B103 in connection with the name change. Outstanding stock certificates will not be affected and will not need to be exchanged.

About MEI Pharma

MEI Pharma, Inc. is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company's lead drug candidates, ME-143 and ME-344, have been shown in laboratory studies to interact with specific enzyme targets resulting in inhibition of tumour cell metabolism, a function critical for cancer cell survival. Marshall Edwards presented safety and pharmacokinetic data from a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumours at the American Society of Clinical Oncology Annual Meeting in June, 2012. The company received approval of its IND application for ME-344 in April, 2012 and a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumours is ongoing. For more information, go to www.marshalledwardsinc.com until 1 July 1, 2012, thereafter www.meipharma.com.

About Novogen Limited

Novogen Limited (ASX: NRT NASDAQ:NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, MEI Pharma, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE
INFORMATION :		COMMUNICATIONS, MARSHALL EDWARDS, INC.
		TEL +1 858-792-3729
		http://www.marshalledwardsinc.com
ISSUED BY	:	WESTBROOK COMMUNICATIONS
CONTACT	:	IAN WESTBROOK TEL (02) 9231 0922